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The FccRI-y chains are expressed in a variety of 
hematopoietic cells where they play a critical  role in 
signal transduction. They are part of the high affinity 
IgE receptor in mast cells, basophils, Langerhans cells, 
and possibly other cells; a component of the low  affinity 
receptor for IgG (FcyRIIIA or CD16)  in natural killer 
cells and macrophages; and  part of the T cell antigen 
receptor in subsets of T cells. Here we have  investi- 
gated the transcriptional regulation of the y chain gene 
by analyzing the 2.5-kilobase sequence upstream of 
the transcription start site.  This sequence contains a 
promoter specific to cells of hematopoietic lineage. 
However, the tissue specificity of this promoter is only 
partial because it  is  active in all of the hematopoietic 
cells tested here, regardless of whether they constitu- 
tively express FccRI- y chain transcripts. We have 
identified two adjacent cis-acting regulatory elements, 
both of which are part of an Alu repeat. The first 
(-445/-366)  is a positive element active in both baso- 
phils and T cells. The second (-365/-264) binds to 
nuclear factors, which appear to be different  in baso- 
phils and T cells, and acts as a negative element in 
basophils and as a positive  one in T cells. Thus, this 
Alu repeat (90% identical to Alu consensus sequences) 
has evolved to become both a positive and negative 
regulator. 
The y chains initially described as subunits of the high 
affinity  IgE receptor (FctRI)’  are  expressed  in  various  hema- 
topoietic cells and are part of several receptor multimeric 
complexes (1-3). Homodimers of y chains,  together  with  an 
a and a chain, form the  tetrameric FccRI receptor  in  mast 
cells, basophils, and Langerhans cells (4-6). The same yy 
homodimers also associate  with  the low affinity  receptor  for 
IgG (FcyRIII, CD16) in  mast cells, basophils, and monocytes 
(7). In  addition  to  forming disulfide-linked  homodimers, the 
y chains  interact with  two other homologous proteins,  the { 
and 71 chains of the T cell antigen receptor. These  three  chains 
generate six different  dimers,  the yy, {{, and 7111 homodimers 
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and  the y{, y ~ ,  and {v heterodimers, all of which associate 
with  the T cell antigen  receptor  in some subsets of T lympho- 
cytes (8-10). The yy, {{ homodimers and  the y{ heterodimers 
are also part of the low affinity IgG receptor (CD16-FcyRIII) 
in  natural killer  cells (11-15). 
The y, {, and 7 chains belong to  the  same family of mole- 
cules. Their respective  genes show a similar genomic organi- 
zation  and  are located on mouse and  human chromosome 1 
(16-23). Furthermore,  they  contain homologous amino acid 
motifs which appear  to  be  critical  to  the  initiation of receptor- 
mediated signal transduction  (3). 
Previously, our laboratory has characterized cDNA and 
genomic  clones  for the  human  FctRI-y  chain  (16).  The gene 
consists of five exons  and  spans 4 kilobases. There is a  major 
start  site localized 25 base  pairs  upstream of the  start codon, 
but a few additional start sites are also present. The gene 
does not show a typical TATA box but contains inverted 
CAAT and GC boxes at positions -199 and -135, respectively. 
This gene is  constitutively  expressed  in  certain cell types such 
as basophils  (1)  but  is only  expressed in  subsets of others cells 
such  as T lymphocytes (8-10). 
In  this  study, we have  characterized  the 5‘ region and  the 
promoter of the  FccRI-y gene and have detected  the  presence 
of positive and negative cis-acting elements.  We show that 
the  promoter  is hematopoietic-specific and  that Alu sequences 
play  a  role in  the positive and negative  regulation of transcrip- 
tion. 
EXPERIMENTAL  PROCEDURES 
Sequencing the 5”Flanking Region of the Human FccRI-y Gene- 
A genomic clone longer than  the one previously described and se- 
quenced (16) was isolated. A 5-kilobase Sal1 fragment was subcloned 
into  the pBSf vector (Stratagene), and a restriction map was estab- 
lished. A 2.2-kilobase HindIII/BglII fragment corresponding to the 5’ 
sequence of the gene  was isolated, subcloned, and sequenced by the 
dideoxy chain termination method using 21-base pair unlabeled oli- 
gonucleotide primers as described before (16). 
Plasmid Construction-DNA from a genomic clone was  used as the 
template  in  a polymerase chain reaction to generate various fragments 
of the 5”flanking region of the FceRI-y gene. Oligonucleotides (24- 
mer) starting at positions -445, -295, -237, -161, -95, and -54 
were chosen as 5’ primer, and  the  3’ primer was the same oligonucle- 
otide ending at position +26. Convenient restriction sites were added 
to each oligonucleotide. The polymerase chain reactions were per- 
formed according to  standard procedures in a 10O-pl reaction volume 
containing 1.5 mM MgC12, 50 pmol of primers, 1 unit of Taq polym- 
erase, and 200 p~ dNTPs.  The polymerase chain reaction products 
were subcloned into the HindIII and XbaI sites of the pCAT-basic 
vector (Promega). 
The -2382/+26 construct was generated by ligation of the -2382/ 
-180 restricted fragment into HindIII and BglII sites of the -445 
construct. The -1631,  -1296, and -365 CAT constructs were gener- 
ated by excising the HindIII and ClaI, HindIII and  PpuMI, HindIII, 
and AccI fragments respectively, from the -2382 construct prior to 
religation. 
The -445 gap (-365,’-264) CAT construct was obtained by a two- 
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step polymerase chain reaction. The -445/-264 (HindIII/AccI) frag- 
ment was inserted upstream (BglII) or downstream (BamHI) of the 
SV40 promoter in the pCAT-promoter vector (Promega). Standard 
procedures were used in all plasmid constructions (24). Both strands 
of each constructs were verified by dideoxy sequencing as above. 
Cells-The CEM-CM-3, Jurkat, HeLa, COS-7, U937, HL-60 cell 
lines were  from the American Type Culture Collection. The human 
basophilic KU812 cell line was a gift from Dr. K. Kishi (25); the 
Daudi cell line was from Dr. M. Schwabe NCI-Frederick, MD; the 
NK 3.3 cell line was a gift from Dr. J. Kornbluth (26). These cells 
were propagated in the recommended media, supplemented with 10% 
heat-inactivated  fetal calf serum, 2 mM glutamine, and antibiotics  in 
a humidified atmosphere of 5% CO, and 95% air. RBL-2H3 cells 
were maintained as described previously (27). 
Transfection-Cells  growing in suspension were transfected while 
in exponential growth, whereas adherent cells were transfected when 
70-80% confluent. DNA  was transfected into HeLa, U937, and COS- 
7 cells by the DEAE-dextran method (24, 28). The other cell lines 
were transfected by electroporation using a Bio-Rad Gene Pulser 
apparatus. 500 p1 of the various cells in complete medium was 
electroporated using the following conditions: 5 X lo6 Jurkat cells, 
300 volts and 500 pF; 5 X lo6 CEM-CM-3 cells, 200 volts and 960 pF; 
1 X IO7 RBL-2H3 cells, 250 volts and 500 pF; 1 X IO7 KU812 cells, 
330 volts and 960 pF. Cotransfection of pCMV-@-galactosidase plas- 
mid (29), which comprises an Escherichia coli LacZ gene driven by 
the cytomegalovirus promoter, was used as a control and to determine 
the best conditions for transfection. Cells were harvested 24 h  after 
transfection, washed  twice with cold phosphate buffered saline, and 
lysed by repeated cycles of freeze-thawing in 250 mM Tris  (pH 7.9). 
Enzyme Assays-The 0-galactosidase assay was performed as de- 
scribed (24) with  10-30  pg of protein. The protein concentration was 
determined by the Bradford method (30). The CAT activity in cell 
lysates, normalized for protein concentrations and for unit of /3- 
galactosidase, was determined by a  slight modification of the method 
described by Gorman et al. (31). In short, the acetylated chloram- 
phenicol was separated from the nonacetylated form by thin-layer 
chromatography and developed in chloroform/methanol (955, v/v). 
The radioactivity of each acetylated and nonacetylated spot was 
directly determined with the Ambis radioanalytic imaging system. 
CAT activity is expressed as acetylated forms/total X 100/100 units 
of @-galactosidase. Every transfection experiment was performed in 
duplicate. The results are expressed as  the means (& S.E. or S.D as 
indicated) of at least three different transfections for each construct 
and for each cell line. 
Nuclear Extract Preparation-Nuclear extracts were prepared as 
outlined by Dignam et al. (32). Buffers A,  C, and D contained 0.5 mM 
phenylmethylsulfonyl fluoride and 0.5 mM dithiothreitol to minimize 
proteolysis. Cells were incubated on ice in 5 volumes of buffer A. 
After 10 min cell membranes were disrupted by 12 strokes of a Dounce 
homogenizer (pestle B), and the intact nuclei were pelleted for 20 
min in a microcentrifuge at 4 "C. The nuclei were broken by 10 
strokes of the Dounce homogenizer in 2 volumes of buffer C and then 
stirred for 30 min at 4 "C. The nuclear extract was then clarified by 
centrifugation (as above) and dialyzed against buffer D for 2 h. The 
total protein concentration was determined by the Bradford method 
(30). Aliquots of nuclear extract were  used immediately or stored at  
-80 "C  for later use. 
Electrophoretic Mobility Shift Assay (EMSAs)-Electrophoretic 
mobility shift assays were performed as described (33) with modifi- 
cations. The double-stranded DNA fragments spanning the sequences 
-445/-180,  -445/-264, and -445/-365  of the y gene were generated 
by enzymatic digestion and isolated by standard techniques (24). The 
fragments were end labeled using [w3'P]ATP and  [c~-~'P]GTP (3000 
Ci/mmol; Amersham Corp.) by Klenow-large fragment polymerase. 
The probe, spanning the region  -366/-290  was generated by synthe- 
sizing two complementary 77-mer oligonucleotides and by annealing 
the two oligonucleotides at  an equimolar ratio  in the presence of 150 
mM NaCI. The resultant double-stranded synthetic oligonucleotide 
was gel purified on a 12% nondenaturing polyacrylamide gel and 
subsequently end labeled with [y-32P]ATP  and  T4 kinase. All probes 
were purified twice over a Sephadex G-25 column. The unlabeled 
double-stranded oligonucleotides used for competition experiments, 
including those corresponding to  the binding sites for NF-kB (34) 
and AP-1 (35 ) ,  were prepared and purified as described above. The 
poly(dA) .poly(dT) double-stranded oligonucleotide was purchased 
from Pharmacia LKB Biotechnology Inc. 
mM Hepes (pH 7.8), 60 mM KC1,0.2 mM EDTA, 1 mM dithiothreitol, 
Binding assays were carried out in a binding buffer containing 20 
1 mM MgCI,, 5% glycerol, about 0.5-1  ng of 3ZP-labeled DNA fragment 
(2 X 10' cpm), 1 or 2 pg  of poly(dI.dC) or poly(dG.dC) (Pharmacia), 
as indicated, and 2-30  pg  of nuclear extract  in  a total volume of  20 
pl. Since the -366/-290 sequence is an AT-rich region and contains 
23 adenines, we performed EMSA with this probe using two different 
nonspecific polyanion competitors (poly(d1 .dC)  and poly(dG. dC))  to 
unmask complexes which  would be undetectable only in the presence 
of poly(dI.dC) (36, 37). For competition experiments, the 100- or 
200-fold molar excess of unlabeled competitor was added to the 
binding reaction 5 min before the radiolabeled probe. Extracts  and 
probes were incubated for 20 min at room temperature and then 
analyzed either on a 5 or  a 8% polyacrylamide nondenaturing 0.5 X 
TBE gel (acry1amide:bisacrylamide ratio of 382) depending on the 
length of the probes. Gels were dried and exposed to Kodak XAR-2 
film without intensifying screens for a few hours or overnight. 
RESULTS AND DISCUSSION 
Consensus Sequences for cis-Acting Elements in the 5'- 
Flanking Region of the  Human  FctRI-y Gene-As a first  step 
in  the  characterization of the regulatory  sequences involved 
in  the  transcriptional  control of the  human FccRI-y chain 
gene, we completed the sequencing of the 5"flanking region 
of the gene from  a  previously  described  genomic  clone (Fig. 
1A).  This allowed us  to localize a number of consensus se- 
quences for potential  cis-acting regulatory elements (Fig. IB), 
among which are  mast-cell specific elements  (GATA), T cell- 
specific elements (Lyf-1, CTF-l), SP-1 sites, an inverted 
CAAT box, several y-interferon- and six interleukin-6-re- 
sponsive elements (38). The  y-interferon  elements  are likely 
involved in the up-regulation of the FccRI-y mRNA levels 
induced by y-interferon in purified monocytes and in the 
U937 cell line.' In  addition, we identified  two Alu repeats,  one 
between -2131 and -2358 and another between -313 and 
-582 from the  ATG start codon (see also below). 
Identification of a Hematopoietic-specific Promoter-To 
identify the  important regulatory elements of the 5"flanking 
region of the gene, we inserted  various  fragments in an  expres- 
sion vector immediately upstream of the chloramphenicol 
acetyltransferase  (CAT) gene and analyzed the effect of the 
various deletions on the transcription of the CAT gene in 
transfected cells. Cotransfection of a  pCMV-@-galactosidase 
plasmid with the CAT constructs allowed the systematic 
monitoring of the  transfection efficiency by enzymatic  assay. 
The  rationale of the  different  deletion  constructs hown in 
Fig. 2A is  as follows. The -95 construct  ends  3' of an SP-1 
site, the -161 construct contains this SP-1 site, the -237 
construct contains the inverted CAAT box, and the -295 
construct  ends 3' of a stretch of 23 consecutive adenines.  The 
remaining  constructs were generated from convenient enzy- 
matic  restriction sites. 
The  analysis of the relative CAT  activity  in  rat basophilic 
leukemia  cells (RBL-2H3),  in  the  human basophilic  cell  line 
KU812, and  in  non-hematopoietic  HeLa cells is shown  in Fig. 
2B. A similar analysis in T cells (the CEM-CM-3 and the 
Jurkat cell lines) and HeLa cells is shown in Fig. 2C. NO 
activity is detected in transfected HeLa cells, regardless of 
the construct and despite a high level of transfection effi- 
ciency. By  contrast,  the -2382 construct  shows a substantial 
activity in basophils (7.4%) and a basal activity in T cells 
(1.7%). However, the -1637 construct  has  no  activity  in  either 
cell type  with  the possible  exception of KU812 cells, in which 
a weak activity is detected.  Furthermore,  the -1296 construct 
shows an  activity  higher  than  the  one observed for  the -1637 
construct,  except  again  in KU812. 
Taken together, these data suggest that the promoter is 
active  in  basophils  and T cells but  not  in  non-hematopoietic 
cells; that  the sequence  between -1296 and -1631 contains a 
' A. Brini  and J.-P. Kinet, unpublished data. 
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FIG. 1. The 5"flanking sequence of the human FceRI-7 
chain gene. Panel A ,  nucleotide sequence of the 2,408-base pair 
fragment  spanning  the 5"flanking region of the human FccRI-y chain 
gene. Position 1 corresponds to the start codon. Alu repeats and 
consensus sequences for GATA, AP-1, AP-2, CF-1, CAMP-responsive 
element, SP-1, and CAAT  box are underlined. The stretches of Alu 
sequences are typed in italics, the Lyf-1 and  TCF-1 binding sites  are 
ouerlined, and the putative "y motif' found three times in the y 
negative element that down-regulates the transcription to 
almost  undetectable levels; that  the sequence  between -1637 
and -2382 confers a basal level of transcription  in T cells and 
a  higher level in  basophils possibly  because of the  presence of 
a  GATA site  found at  -1807. 
To  confirm the specificity of the  promoter  for hematopoietic 
cells we also transfected COS-7 cells, the monocytic cell line 
U937, and  the B cell line  Daudi,  with  the -2382 construct. 
No activity was detected  in  non-hematopoietic COS-7 cells, 
whereas a basal  CAT  activity was observed in U937 and  Daudi 
cells (data  not  shown). 
The Promoter Confers Only Partial Tissue Specificity- 
Among the hematopoietic cells chosen for transfection, the 
RBL-2H3, KU812, CEM-CM-3,  and U937 cells express 
FctRI-y  transcripts  constitutively,  whereas  Jurkat  and Daudi 
cells do  not. However, there  is  no difference in  the  promoter 
activity  in  the  transfected cells  according to  whether or not 
they  express  the  FctRI-y  transcripts.  Therefore,  the  promoter 
analyzed  here is responsible for only part of the  tissue speci- 
ficity (i.e. hematopoietic)  but  not for the complete  specificity 
(i.e. transcription  in  FctRI-y-positive cells). It  is possible that 
other regions of the gene may control  the specificity of expres- 
sion  in  FctRI-y-positive cells. More likely, gene methylation 
may confer that specificity as shown for the gene of the ( 
chain of the T cell antigen  receptor, a gene homologous to  the 
y gene analyzed here (39) and for other genes as well (40). 
Alternatively,  the  interaction of nuclear factors with the gene 
may be affected by different  DNA  structures  in various cell 
types. 
The -445/-295 Fragment Contains a Strongly Positive, 
Hematopoietic-specific Element-The most significant finding 
of the  functional  analysis  with  the deletion constructs  is  the 
identification of a strongly positive region between -445 and 
-295 (Fig. 2, B and C). This  element  is  at  least four times 
more potent  in  basophils  than  in T cells and  is  inactive  in 
HeLa cells. I t  is 30 X more potent  in  RBL cells than  the SV40 
promoter and 3 X more potent in T cells (not shown). In 
addition,  it is active  in  many  other hematopoietic  cells  includ- 
ing U937, THP1, and HL-60, NK 3.3, murine CTLL and 
Daudi  but  not  in  COS-7  (not  shown), co firming its specificity 
to cells of hematopoietic lineage. However, similar  to  what is 
observed  for the  full-length  construct,  this  element is active 
in  both  FctRI-y-negative  and FccRI-y-positive  hematopoietic 
cells. 
Effect of the -445/-264 Fragment on a Heterologous Pro- 
moter-To test if the -445/-264 region could  also up-regulate 
the  activity of a  heterologous promoter, we inserted  the -445/ 
-264 fragment upstream or downstream of the SV40 pro- 
moter-driven  CAT gene (Fig.  3A). The fragment has no 
apparent effect on the transcription of the CAT gene i,n 
transfected T cells, but it has a surprising  inhibitory effect in 
transfected  RBL cells (Fig. 3B).  This  inhibitory effect is only 
seen  when the  fragment  is  inserted 5' of the  CAT gene and 
in  the forward orientation.  The  inhibitory effect is not  seen 
when the  insert is placed  in the reverse orientation  (data  not 
shown). One possibility is  that  binding of basophil-specific 
nuclear  factors  to  this region interferes nonspecifically  with 
the  functioning of the SV40 promoter.  Another possibility is 
that  this region contains a  basophil-specific  negative element 
(see below). In  any case, the negative effect of this  fragment 
is nullified  when the  downstream sequence of the homologous 
promoter  is  present.  In  addition,  the  disparate effects  observed 
promoter region is highlighted in boldface.  Panel E ,  list, number, and 
position of the putative regulatory elements corresponding to the 
consensus sequences as indicated. The consensus sequences are listed 
in the IUPAC-IUB code (38). 
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FIG. 2. Functional analysis of the 5"flanking sequence of 
the human y chain gene by CAT assay. Panel A ,  schematic 
representation of the human FceRI-y gene chimeric CAT plasmids. 
Panel B, CAT activities of the various deletions constructs  transfected 
into human (KU812 cells) and  rat (RBL-2H3 cells) basophils. The 
levels of  CAT activity detected in  HeLa cell lysates are also shown. 
Panel C, CAT activities in  transfected human T lymphocyte cell lines 
(CEM-CM-3 and  Jurkat) and  in HeLa cells. The relative CAT activity 
is expressed as percent of conversion of the chloramphenicol to  its 
acetylated forms. The graphics represent the averages of the relative 
CAT activity k S.E.  from at least five separate  transfections for each 
construct and for each cell line. Each transfection was done in 
duplicate. The CAT activities have been standardized by using units 
of the &galactosidase activity resulting from the cotransfection of 
the pCMV-fl-galactosidase plasmid. 
in T cells and basophils support our contention that the 
nuclear  factors  interacting with this region are  different  in T 
cells and in basophils (see below). 
The -4451-264 Fragment  Binds to Specific Nuclear Fac- 
tors-We analyzed by EMSA the capacity of the Hind1111 
AccI fragment (-4451-264) to bind to specific nuclear factors 
extracted from the cells used in  the functional  analysis (Fig. 
4). Nuclear proteins  extracted from Jurkat, CEM-CM-3, and 
RBL cells bind to this fragment. This binding is blocked 
A 
pSVWCAT 
SV40  PROMOTER 
e BamH ;;alto 3' 
, , SV40  PROMOTER SV40 PROMOTER 
445 -264 
-
Hind I l l  ACC I 
-445 -264 
Hind 111 Ace I 
T 
RBL.2H3 Jurkal 
FIG. 3. Effect of the transcriptionally active human y se- 
quences on a heterologous promoter. Pawl A, schematic repre- 
sentation of SV40 early promoter-CAT constructs made to  test  the 
effect of the -445/-264 y region on a heterologous promoter. The 
control plasmid is the vector pSV40-CAT (B). The -445/-264 human 
y fragment was inserted 5' (a) or  3' (0) of the SV40 promoter. Panel 
B,  functional analysis of SV40 promoter constructs  transiently trans- 
fected in RBL-2H3 cells or in Jurkat cells. The CAT activity was 
determined as in Fig. 2. The bars represent the average percent of 
conversion of CAT to its acetylated products & S.D. of three  separate 
transfections, each performed in duplicate. 
efficiently by using unlabeled -445/-180 (lanes 4,9,  and 14) 
or -3661-290 fragments (lanes 5, 10, and 15) but not by 
unrelated ones (lanes 3, 6, 8, 11, and 13). Therefore, nuclear 
factors  binding specifically to  the -4451-264 region are pres- 
ent in these cells. Furthermore, the different patterns ob- 
tained  with nuclear extracts from RBL cells and from Jurkat 
or CEM-CM-3 cells suggest that the factors binding this 
region are different  in T cells and basophils. 
We also tested the binding capacity of the -4451-180 
fragment (not shown). We observed no specific binding with 
a nuclear extract from HeLa cells but found virtually the 
same patterns of retarded bands with nuclear extracts from 
Jurkat, CEM-CM-3, and RBL cells as  those shown in Fig.  4. 
This suggests that  the -2641-180 region does not participate 
in  the binding of specific nuclear factors. 
The -3661-290  Region Binds to Nuclear Factors That Are 
Different in Basophils and T Cells-Since the -3661-290 
fragment is an efficient inhibitor of the binding of nuclear 
factors to  the -4451-264 region, we decided to use the radi- 
olabeled -3661-290 fragment itself in binding studies (Fig. 
5A). As expected, the  patterns of retarded  bands  are  different 
when the binding is performed in the presence of poly(d1 .dC) 
or of poly(dG.dC) (36, 37). Regardless of the conditions, the 
patterns of retarded bands are also different  in T cells (Jurkat 
and CEM-CM-3) and basophils (RBL-2H3 and KU812). 
These results are consistent with those obtained with the 
larger -4451-264 fragment, suggesting once again that  the 
nuclear factors  interacting with this region are  different  in 
basophils and T cells. 
We subsequently studied the capacity of short, double- 
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FIG. 4. Binding of nuclear proteins to the (-4451-264) 
fragment of the FccRI--y chain gene. Analysis was by EMSA. 
Panel A ,  schematic representation of probes and DNA fragments 
used in EMSAs. The top of the figure shows a partial restriction map 
of the region between -445 and +26. Panel B, EMSA performed with CEUEM-3 n u c h 8 r e x t ~ ~ t  
nuclear extracts from Jurkat cells (lanes 2 4 ,  CEM-CM-3 cells (lanes C 
7-11), and RBL-2H3 cells (lanes 12-15). Nuclear extracts were F 
incubated with the 32P-labeled -445/-264 fragment in the presence Comptltor: I 3 p g f a s q ,  j . $ $ $ $ $ ? 5 -  
of poly(d1 .dC)  as nonspecific competitor. Lane 1 contains  the labeled 
probe alone. Unlabeled DNA fragments used as competitors are 
indicated. 7 L. 
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8 
stranded oligonucleotides to inhibit specific binding to  the 
- *C)l 
-3661-290 element in RBL-2H3 cells (Fig. 5B)  and CEM- 
CM-3 cells (Fig. 5C). Two major bands  in  RBL cells and one 
major band in CEM-CM-3 cells are detected in the presence 
of the unlabeled NF-kB and AP-1  (lanes 12 and 13) and  are 
therefore considered to be specific. These bands are not 
observed following competition with the homologous cold 
fragment  (lane 9) but  are observed following competition with 
the -3841-365 oligonucleotide, whose sequence is located 5' 
of the relevant sequence (lane 3) .  
The -3641-345 oligonucleotide is inhibitory in  RBL cells 
and may have a slight inhibitory effect in CEM-CM-3 cells 
(lane 4 ) .  Since a Lyf-1 motif is present in  the -3641-345 
region, Lyf-binding factors already known to be present  in 
various B and T lymphocytes could potentially explain the 
hematopoietic specificity of the promoter. However, the  sur- 
prising finding that  the -2841-260 (lane 8) and -50/+26 
(lane IO) oligonucleotides also inhibit binding in  RBL cells 
but not  in CEM-CM-3 cells led us  to speculate that a sequence 
other than the Lyf-1 motif might also be involved in the 
binding. Indeed, sequence comparison between these two oli- 
gonucleotides and  the -3661-290 element reveals a common 
motif if one allows for two mismatches. This motif is not 
found anywhere else in the 2.4 kilobases of the 5' region. The 
sequence GCACTCCAGC is found at  -355 right after the 
Lyf-1 motif, the sequence GatCTCCAGC is found at  -15, and 
the complementary sequence to cCACTCCAcC is found at  
-277. Therefore, it is conceivable that  the presence of this 
common motif explains the inhibitory effect of the -2841 
-260 and -50/+26 oligonucleotides in  RBL cells. It is also 
1 2 3  4 5 6 7 8 9 1 0 1 1 1 2 1 3  
FIG. 5. Binding of specific nuclear proteins to the -3661 
-290  fragment of the FccRI-y gene promoter. Panel A ,  EMSA 
performed with nuclear extracts from Jurkat, CEM-CM-3, HeLa, 
RBL-2H3, and KU812 cell lines as in Fig. 4. Nuclear extracts were 
incubated with the 3*P-labeled -366/-290 fragment in the presence 
of poly(d1-dC) or poly(dG.dC) as nonspecific competitor. Panels B 
and C, EMSA performed with nuclear  extracts from RBL-2H3 and 
CEM-CM-3 cell lines as in panel A and with the poly(dG.dC) as 
nonspecific inhibitor. DNA fragments used as competitors are indi- 
cated. 
tempting to speculate that  the same basophil-specific factors 
interact with these  three motifs. This could explain why the 
-4451-264 fragment  has  a different activity when  placed in 
front of a heterologous promoter (see above). Obviously, fur- 
ther characterization of the motif and of possible binding 
factors needs to be  done. 
Detection of Two Adjacent Regulatory Elements in the -4451 
-264 Region-To analyze further  the differential function of 
the -4451-264 fragment in basophils and T cells, we studied 
additional deletion constructs (Fig. 6). Removing the region 
between -365 and -264 results in an 89% increase in CAT 
activity in basophils when compared with the complete  -4451 
+26  region. In contrast,  no significant difference is detected 
1360 Transcriptional Regulation of the FccRI-7 Chain Gene 
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FIG. 6. Functional analysis of the -4451-264 region: detection of two adjacent regulatory elements. Panel A,  schematic 
representation of the human  FcrRI-y gene CAT constructs. Panel B, CAT activities in  transfected RBL-2H3 and in CEM-CM-3 cells.  CAT 
activities were analyzed as in Fig. 2 from at least three independent transfection for each construct. The  data have been normalized as 
follows. The activities corresponding to  the -2382 and to  the -445 CAT construct were considered as 1 and 100, respectively. The mean -t 
S.D. are shown for each construct. The differences of CAT activity between the -445 and  the -445 gap (-3651-264) CAT on the one hand, 
and between the -445 and -366 CAT constructs on the  other  hand  are  both highly significant in  RBL-2H3 cells ( p  < 0.01). 
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FIG. 7. Alignment of the  cis-acting  regulatory  elements ( I )  
with the primate-specific Alu consensus sequence (ZI). The 
adjacent cis-acting regulatory elements of the y chain gene are 
underlined. The consensus Alu sequence corresponds to  the primate- 
specific Alu consensus sequence (41). The stretch of consecutive 
adenines is typical of the 3' portion of Alu sequences, although the 
number of these adenines is variable. Here only 18 out of the 23 
adenines found in the y chain gene are shown. Double dots indicate 
identical nucleotides, and dashes correspond to  gaps or deletions. 
in T cells. Therefore the -3651-264 element is a negative 
regulator  in  basophils  but  not  in T cells. 
Deletion of the -4451-366 region abolishes the  CAT  activ- 
ity in RBL cells but yield only a 40% reduction in  CEM-CM- 
3 cells. Indeed in  CEM-CM-3 cells, a further  deletion of the 
-3651-295 region is required to reduce the  CAT  activity  to 
basal level (see Fig. 2). These  results  indicate  that  the -4451 
-366 element is a positive element in both  basophils  and T 
cells  and  that  the -365/-264 element  contains  an  activator 
in T cells but  not  in basophils. 
The Two cis-Acting Regulatory Elements  Are Part of an  Alu 
Repeat-As mentioned above, the 5' sequence of the y chain 
gene  contains two  typical Alu repeats (Fig. 1). Comparison of 
the sequence containing the two cis-acting regulatory ele- 
ments (-4451-366 and -3651-264 elements) with Alu con- 
sensus sequences shows that the regulatory elements are 
within  the sequence of Alu repeats. Among all subfamilies of 
Alu sequences (41), the  best  alignment was with  the  primate- 
specific Alu consensus  sequence. We found  that  about 90% of 
the nucleotides are  identical between the two  sequences  (Fig. 
7) .  
There  are examples of Alu sequences containing negative 
regulatory elements (42, 43), but we are not aware of any 
example of positive regulatory elements containing Alu se- 
quences. Clearly the  entire (-4451-366)-positive element is 
part of the Alu repeat. Most of the other element (-3651 
-264) overlaps  also  with the Alu consensus sequence, but we 
cannot exclude that  the sequence from -296 to -264, which 
is not part of the Alu repeat, is critical for its activity. 
However, our binding  studies suggest that  the  active region 
of the (-365/-264) element  is between -365 and -290 and 
is  within  the Alu repeat. 
In conclusion, we have  shown that  the  transcription of the 
FccRI-7 chain  gene is regulated  by  positive and negative  cis- 
acting  elements.  These  elements  are  part of an Alu repeat, 
are only active  in  hematopoietic cells, and  are recognized by 
DNA-binding  proteins  in a cell type-specific manner. 
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